CD30+ peripheral T-cell lymphoma
Haematology · 2021–2021
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| brentuximab vedotin Treatment of adult patients with previously untreated CD30 positive peripheral T-cell lymphoma (PTCL) in combination with cyclophosphamide, doxorubicin, and… | Mar 2021 | Recommended with restriction | input received Rare Cancers Australia · Leukaemia Foundation · Haematology Society · Lymphoma Group |
Who spoke
Rare Cancers Australia · Leukaemia Foundation · Haematology Society · Lymphoma Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.